Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Elicio Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
2.88
28.3
2.3
Cost of revenue
1.19
0.43
0
Gross profit
1.69
27.9
2.3
Research and development
39
48.7
18.1
23.8
33.7
24.9
General and administrative
18
18.5
5.63
11.9
11.3
12.8
Operating income
-55.3
-39.3
-23.7
-35.7
-45
-37.7
Interest expense
3.6
1.06
0.46
1.13
Other non-operating income
-24.8
-15.3
-4.48
0.55
-6.91
-1.86
Pre-tax income
-80.1
-54.6
-38.8
-51.9
-39.6
Income tax
0
0
0
0
0
0
Net income
-80.1
-54.6
-28.2
-35.2
-51.9
-39.6
EBITDA
-55.2
-39.2
-23.3
-35.4
-44.7
-37.5
EPS, basic
-375.77
-133.56
-89.27
-6.96
-4.25
-2.58
EPS, diluted
-375.76
-133.56
-89.27
-6.96
-4.25
-2.58
Shares, basic (weighted)
0.21
0.41
0.32
5.06
12.2
15.3
Shares, diluted (weighted)
0.21
0.41
0.32
5.06
12.2
15.3
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
34.6
88.8
6.16
12.9
17.6
18.6
Receivables
0
Other current assets
0.36
0.5
0.25
2.73
1.9
0.75
Total current assets
42.3
91.2
10.7
16.3
20.7
19.3
Property, plant and equipment
0.16
0.45
1.15
0.72
0.48
0.3
Lease right-of-use assets
4.07
3.99
7.35
6.56
5.71
4.78
Other non-current assets
0
0.11
0.06
Total assets
47.3
96.5
22.7
27.1
28.2
25.9
Accounts payable
5.58
4.71
2.81
4.37
1.04
0.67
Accrued liabilities
6.67
3.22
1.94
3.76
8.42
6.43
Deferred revenue
3.94
2.3
1.44
0.69
1.17
0
Total current liabilities
107
11.3
6.87
9.76
11.5
8.11
Long-term debt
0.64
0
20
9.41
Lease liabilities
3.85
3.48
6.79
6.01
5.11
4.09
Other non-current liabilities
0
Total liabilities
138
15
13.7
15.8
39.5
24.2
Total debt
0.64
0
20
10
Paid-in capital
72.1
296
4.86
154
183
235
Retained earnings
-161
-215
-107
-142
-194
-234
Treasury stock
-1.85
0
0
-0.15
-0.15
-0.15
Other comprehensive income
-0.33
-0.1
0
-0.2
-0.18
-0.13
Shareholders' equity
-90.4
-74.5
-102
11.4
-11.3
1.64
Total equity
-90.4
-74.5
-102
11.4
-11.3
1.64
Total liabilities and equity
47.3
96.5
22.7
27.1
28.2
25.9
Shares outstanding
0.22
0.43
0.32
9.6
11
17.8
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-80.1
-54.6
-28.2
-35.2
-51.9
-39.6
Depreciation and amortization
0.1
0.09
0.39
0.38
0.32
0.2
Stock-based compensation
4.72
12
0.58
1.18
1.45
2.7
Deferred income tax
0
0
0
0
0
Change in payables
-5.61
-0.87
1.13
0.02
-3.33
-0.37
Cash from operations
-22.9
-52.6
-22.2
-32.7
-37.1
-37
Capital expenditures
-0.04
-0.38
-0.65
-0.07
-0.09
-0.02
Cash from investing
-0.04
-0.38
-0.65
-0.03
-0.08
-0.02
Debt issued
0
19.7
0
Stock issued
-0.52
107
0
7
4.56
16.2
Share buybacks
0
-0.15
0
Cash from financing
52.4
107
21.2
38.6
42.3
36.7
Exchange rate effect
-0.44
0
0
0
0.02
0.05
Net change in cash
29
54.1
-1.63
5.89
5.19
-0.23
Free cash flow
-22.9
-53
-22.8
-32.8
-37.2
-37
Interest paid
0
0.01
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.84 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-476.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-120.8%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-8.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
4.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-11.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
25.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
264.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
135.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.77x
Current assets / current liabilities.
Quick ratio
2.55x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.55x
(Cash + short-term investments) / current liabilities.
Debt / equity
1.20x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
30.4%
Total debt / total assets.
Liabilities / assets
74.7%
Total liabilities / total assets.
Net debt
-$13.9M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.96
Cash from operations / diluted weighted shares.
Book value per share
$0.36
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
6.09x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
6.09x
Market cap / tangible book value, when positive.
Earnings yield
-78.3%
Net income / market cap (the inverse of P/E).
Was Elicio Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $39.6M.
How much free cash flow did Elicio Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $37.0M minus capital expenditures of $16.0K left free cash flow of -$37.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.